Andrew C. Barrett, Ph.D. - Chief Scientific Officer
Dr. Andrew Barrett has over 25 years of experience in academia and industry and is widely regarded as an expert in CNS pharmacology and therapeutics. Dr. Barrett earned his Ph.D. in Neuroscience at University of North Carolina at Chapel Hill and completed his Postdoctoral Fellowship in Addiction at Harvard Medical School/McLean Hospital, where he conducted research on medications development for Substance Use Disorders. Dr. Barrett received funding from the National Institute on Drug Abuse (NIDA) to complete both his doctoral and postdoctoral training and remains passionate about identifying and developing candidate medications for Substance Use Disorders. Prior to joining Cessation, Dr. Barrett held positions of increasing seniority at Cephalon (acquired by Teva in 2011), Synchrony Healthcare, Salix Pharmaceuticals (acquired by Valeant in 2015), and KemPharm. Dr. Barrett has published over 40 original manuscripts in peer-reviewed journals, focusing primarily on the abuse-related effects of opioids, stimulants, and other drugs.